Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q2 2022
Net profit, assets, equity and cash flow for Q2 2022, against the same period a year earlier, from the published financial statements.
Net profit40.68 millionEGP
Total assets639 millionEGP
Shareholders' equity360 millionEGP
Operating cash flow-13.41 millionEGP
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q2 2022 was about 40.68 million EGP.
- Total assets at the end of Q2 2022 were about 639 million EGP, and shareholders' equity about 360 million EGP.
- Operating cash flow for Q2 2022 was negative at 13.41 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit40.68 million——
Gross profit133 million——
Total assets639 million——
Total liabilities279 million——
Shareholders' equity360 million——
Total liabilities and equity639 million——
Operating cash flow-13.41 million——
Investing cash flow-1.7 million——
Financing cash flow-24.3 million——
Net change in cash-39.4 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy